🧬 BioMed Pulse · 2026-11-19 02:01 UTC
BIOMED PULSE
Daily Briefing on Longevity, Viruses & New Cures
Thursday, 19 November 2026 — 02:00 UTC
⚡ TL;DR
The Bundibugyo virus disease outbreak in the Democratic Republic of the Congo remains the defining global health crisis of 2026, now spanning 61+ health zones across six provinces and exporting cases to Kenya and Nigeria — the largest Ebola-family outbreak ever recorded. Mood: gravely urgent on outbreak containment; cautiously optimistic on longevity science, with new aging-clock tools and physical-activity frameworks reaching publication.
🦠 OUTBREAKS & VIRUSES
BUNDIBUGYO VIRUS DISEASE (DRC, KENYA, NIGERIA) — CRITICAL ESCALATION
- As of the most recent WHO Disease Outbreak News, the BVD outbreak has spread to at least 61 health zones across six DRC provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, plus a new foothold in Sud Ubangi province. [1]
- An imported laboratory-confirmed BVD case in Kenya was reported to WHO on 5 October 2026; the patient had travelled from DRC through Uganda before hospitalization. [2]
- Nigeria subsequently joined Kenya as an affected country outside DRC, with WHO noting sustained high-level transmission across the region in its 23 October update. [3]
- The 6 November WHO update confirmed the outbreak continues expanding geographically within DRC while some localized areas show a slight case decline — transmission has not been broken. [4]
- WHO describes this as the largest Ebola-family outbreak ever reported in DRC and notes it is expanding faster than any previous Ebola outbreak, driven by sustained community transmission. [5]
- Cumulative confirmed cases surpassed 2,124 with 828 deaths as of 15 July 2026; figures are substantially higher in later postings. [6]
CHIKUNGUNYA VIRUS — FIRST LOCAL TRANSMISSION IN SWITZERLAND
- On 4 November 2026, health authorities in the canton of Ticino, Switzerland reported four locally acquired chikungunya virus disease cases — the first ever documented local transmission in the country. [7]
- Ticino borders northern Italy, where Aedes mosquito vectors are established; WHO has been notified and surveillance is ongoing. [7]
SHAMONDA VIRUS — FIRST DOCUMENTED HUMAN INFECTION (FRANCE)
- France notified WHO on 20 October 2026 of the world's first confirmed human infection with Shamonda virus (SHAV), an orthobunyavirus; the case was an immunocompromised older man from eastern France with no recent travel history. [8]
- The patient developed severe neurological symptoms; SHAV is an animal-associated orbivirus-related pathogen not previously recorded in humans, making this a novel spillover event. [8]
MERS-CoV — SAUDI ARABIA AND QATAR
- Saudi Arabia reported eight laboratory-confirmed MERS-CoV cases including one death between 1 January and 5 October 2026, spread across six locations including Riyadh, Tabuk, and Al Jouf. [9]
- Qatar notified WHO on 29 October 2026 of two laboratory-confirmed MERS cases confirmed in August 2026, described as the first MERS cases reported by Qatar in the current notification period. [10]
YELLOW FEVER — AFRICA AND THE AMERICAS
- In the WHO African Region, 67 confirmed cases including 18 deaths were recorded across nine countries from 1 January to 12 October 2026, with recent activity concentrated in West Africa including Burkina Faso, Cameroon, and the Central African Republic.
- Globally, six countries reported 79 human yellow fever infections through 26 May 2026, following elevated transmission in the Americas during 2025 that carried into 2026.
NIPAH VIRUS — INDIA
- Kerala State, India confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district on 11 June 2026; the adult male patient presented with neurological symptoms after onset on 30 May and was hospitalized 10 June.
HANTAVIRUS — CRUISE SHIP MULTI-LOCATION CLUSTER
- WHO posted its fifth Disease Outbreak News update on the Andes hantavirus (ANDV) cluster linked to cruise ship M/V Hondius, originally notified to WHO on 2 May 2026 as severe acute respiratory illness cases on board.
U.S. MEASLES ELIMINATION STATUS LOST
- CDC and partners issued a joint statement on 17 November 2026 announcing the loss of U.S. measles elimination status, with plans to stop ongoing outbreaks and restore elimination.
PNEUMONIA OF UNDETERMINED ETIOLOGY — RUSSIA
- WHO was alerted on 2 October 2026 to the death of an employee of the Irkutsk Antiplague Research Institute of Siberia following severe pneumonia; the etiology remains under investigation.
🧬 LONGEVITY & AGING
AGING CLOCKS FROM ELECTRONIC HEALTH RECORDS
- A new framework called ClinicalAge, developed using longitudinal UK electronic health records, models individual aging trajectories and has been validated as a tool that may outperform chronological age in predicting health outcomes.
- A companion paper in Lancet Digital Health introduces a novel aging biomarker derived from the same type of longitudinal EHR data, designed to capture how fast — or slowly — a person is biologically aging over time.
- Researchers argue that physical function and muscle health metrics serve as "clinically meaningful aging clocks" that better reflect true biological age than a birthdate alone.
AI AND FACE PHOTOGRAPHS AS AGING BIOMARKERS
- A model called FAHR-Face (Foundation AI for Health Recognition by Face), developed with contributions from Gladyshev VN and Aerts HJ among others, uses facial photographs to capture aging signals and was published in Lancet Digital Health; the study reports both model development and external validation.
GDF11 AND MUSCLE AGING / SARCOPENIA
- Research published in Genes & Disease (Zhang F.) shows that GDF11, a circulating protein, restores skeletal muscle satellite cell function via the MYC transcription factor, ameliorating sarcopenia — age-related muscle loss — in preclinical models.
- Sarcopenia is a major driver of frailty, falls, and loss of independence in older adults, making GDF11-pathway targets a point of significant translational interest.
SENESCENCE AND CANCER IMMUNOTHERAPY
- A study in Biomaterials (Yang Z et al.) describes hybrid nanovesicle artificial antigen-presenting cells that integrate tumor antigen display with senescence-mimetic erythrocyte membrane signals to prime T-cells in the spleen, suggesting senescence biology can be co-opted to boost anti-tumor immunity.
- A separate paper (Wang W et al., Bioactive Materials) used PSMA-targeted nanoparticles delivering ATR and Src/Bcr-Abl inhibitors to stimulate the STING pathway and reprogram the senescence-associated secretory phenotype (SASP), enhancing immunotherapy efficacy in prostate cancer models.
PHYSICAL ACTIVITY AND HEALTHY AGING — LANCET SERIES
- A multi-paper series in Lancet Healthy Longevity calls physical activity promotion for older adults in low- and middle-income countries "a public health priority," citing evidence that activity interventions reduce dementia risk, frailty, and cardiovascular disease.
- One paper in the series (Koemel NA, Valenzuela PL et al.) systematically reviews the evidence linking physical activity and reduced sedentary time to healthy aging outcomes in older adults globally.
- King AC et al. published a scoping meta-review of progress and future prospects for physical activity promotion in later life, calling for multilevel societal action.
- A clinical-to-implementation paper (Sánchez-Sánchez LL et al.) translates physical exercise intervention research — covering resistance, aerobic, and multimodal training — into guidance for clinical practice in aging populations.
ANIMAL PROTEIN, COGNITION, AND DEMENTIA DISPARITIES
- An ecological analysis (You W et al., Future Science OA) examined associations between national animal protein supply, cognitive aging rates, and female-male dementia disparities globally, suggesting protein availability patterns may partly explain observed sex differences in dementia prevalence.
ANABOLIC SENSITIVITY AND PROTEIN ACROSS THE LIFESPAN
- A ClinicalTrials.gov-registered study (NCT06744491) is testing an oral breath test to measure how anabolic sensitivity — the muscle-building response to a protein meal — differs across age groups, biological sexes, and physical activity levels, with implications for nutritional recommendations in older adults.
💊 NEW CURES & APPROVALS
PIMJETMI (PIMICOTINIB) — EMD SERONO — ORIGINAL APPROVAL
- EMD Serono received an original FDA approval (ORIG AP) for PIMJETMI, containing the active ingredient pimicotinib, a CSF1R inhibitor for tenosynovial giant cell tumor; NDA 220414.
KLYGEFA (GEFURULIMAB) — ALEXION PHARMACEUTICALS — ORIGINAL APPROVAL
- Alexion Pharmaceuticals received an original FDA biologics approval (ORIG AP) for KLYGEFA, containing gefurulimab; BLA 761488 — a complement pathway-targeting antibody.
PEBRILZO (PERTUZUMAB BIOSIMILAR) — BIOCON BIOLOGICS INC — ORIGINAL APPROVAL
- Biocon Biologics received an original FDA biologics approval (ORIG AP) for PEBRILZO, a biosimilar of pertuzumab (HER2-targeted antibody used in breast cancer); BLA 761501.
GAVRETO (PRALSETINIB) — RIGEL PHARMACEUTICALS — SUPPLEMENTAL APPROVAL
- Rigel Pharmaceuticals received a supplemental FDA approval (SUPPL AP) for GAVRETO (pralsetinib), a RET kinase inhibitor used in RET-altered non-small cell lung cancer and thyroid cancers; NDA 213721.
LAZCLUZE (LAZERTINIB MESYLATE) — JANSSEN BIOTECH — SUPPLEMENTAL APPROVAL
- Janssen Biotech received a supplemental FDA approval for LAZCLUZE (lazertinib mesylate), a third-generation EGFR inhibitor used in EGFR-mutated non-small cell lung cancer; NDA 219008.
MYQORZO (AFICAMTEN) — CYTOKINETICS — SUPPLEMENTAL APPROVAL
- Cytokinetics received a supplemental FDA approval for MYQORZO (aficamten), a cardiac myosin inhibitor for hypertrophic cardiomyopathy; NDA 219083.
IMFINZI (DURVALUMAB) — ASTRAZENECA — SUPPLEMENTAL APPROVAL
- AstraZeneca received a supplemental FDA approval for IMFINZI (durvalumab), a PD-L1 checkpoint inhibitor with an expanded or updated indication; BLA 761069.
GAZYVA (OBINUTUZUMAB) — GENENTECH — SUPPLEMENTAL APPROVAL
- Genentech received a supplemental FDA approval for GAZYVA (obinutuzumab), a CD20-targeting monoclonal antibody used in chronic lymphocytic leukemia and follicular lymphoma; BLA 125486.
ZOKINVY (LONAFARNIB) — SENTYNL THERAPEUTICS — SUPPLEMENTAL APPROVAL
- Sentynl Therapeutics received a supplemental FDA approval for ZOKINVY (lonafarnib), a farnesyltransferase inhibitor originally approved for Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies; NDA 213969.
ZURZUVAE (ZURANOLONE) — BIOGEN — SUPPLEMENTAL APPROVAL
- Biogen received a supplemental FDA approval for ZURZUVAE (zuranolone), a neuroactive steroid GABA-A receptor modulator for depression; NDA 217369.
LUMRYZ (SODIUM OXYBATE) — ALKERMES — SUPPLEMENTAL APPROVAL
- Alkermes received a supplemental FDA approval for LUMRYZ (sodium oxybate), an extended-release once-nightly formulation for narcolepsy with cataplexy; NDA 214755.
🧪 CLINICAL TRIALS
PHYSICAL FRAILTY INTERVENTION FOR OLDER ADULTS WITH HYPERTENSION (NCT07946744)
- A study registered 18 November 2026 is evaluating a 12-week nurse-led Physical Frailty Intervention Module (PFIM) for older adults with both hypertension and physical frailty, measuring physical function, independence, and quality of life outcomes.
ACUTE HOSPITAL CARE AT HOME FOR PEOPLE LIVING WITH DEMENTIA (NCT06819852)
- A parallel-group multicenter randomized controlled trial is testing a 1-year pre-enrolled acute hospital-care-at-home intervention versus usual inpatient care for dementia patients, with family caregiver agreement required for enrollment.
REDUCING INAPPROPRIATE PRESCRIBING IN OLDER ADULTS IN THE ED (NCT07146763)
- A cluster-randomized trial is assessing whether feedback about potentially inappropriate medications (PIMs) — delivered by either peer clinician prescribers or anonymous systems — improves guideline-concordant prescribing for older adults visiting emergency departments.
ANABOLIC SENSITIVITY BREATH TEST ACROSS THE LIFESPAN (NCT06744491)
- An observational study is using a novel oral breath test methodology to measure muscle anabolic response to a liquid protein meal, comparing responses across age groups, sexes, and physical activity levels — data relevant to protein intake guidance for healthy aging.
MODEL-GUIDED ANTIBIOTIC DOSING IN ELDERLY PNEUMONIA PATIENTS (NCT07945275)
- A superiority study is testing pharmacokinetic model-guided individualized dosing of piperacillin-tazobactam in older adults with community-acquired pneumonia, comparing it to standard empirical every-8-hour dosing to optimize outcomes in an age group with altered drug clearance.
MALARIA TRANSMISSION-BLOCKING VACCINE Pvs230D1-EPA/MATRIX-M (NCT07930585)
- A trial registered 18 November 2026 is testing the Pvs230D1-EPA/Matrix-M transmission-blocking vaccine against Plasmodium vivax malaria in healthy malaria-naive adults, using a controlled human malaria infection and transmission model to assess efficacy.
📢 PUBLIC HEALTH
U.S. MEASLES ELIMINATION STATUS — URGENT ACTION CALLED
- CDC jointly declared on 17 November 2026 that the U.S. has lost measles elimination status and outlined a plan — including outbreak response and vaccination drives — to restore it; this follows years of declining vaccine coverage in some communities.
FALLS REMAIN THE LEADING CAUSE OF INJURY DEATH IN OLDER AMERICANS
- CDC data show that an older adult falls every second in the United States, making falls the number-one cause of both injuries and injury-related deaths in this age group — a figure with direct relevance to frailty and aging-in-place policy.
NOTE: This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for personal health decisions.
📎 Sources
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
- Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
- Chikungunya virus disease - Switzerland — WHO Disease Outbreak News
- Shamonda virus in human - France — WHO Disease Outbreak News
- Middle East respiratory syndrome coronavirus - Kingdom of Saud… — WHO Disease Outbreak News
- Middle East respiratory syndrome (MERS) – Qatar — WHO Disease Outbreak News
Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20261119-02-v140 · 2026-11-19 02:01 UTC · pulse.uzylab.com